The persistence of tadalafil monotherapy and the reasons for withdrawal from treatment of treatment-naive patients with benign prostatic hyperplasia in the real-world clinical setting

The persistence of tadalafil monotherapy and the reasons for withdrawal from treatment of treatment-naive patients with benign prostatic hyperplasia in the real-world clinical setting - Persistence and reasons for withdrawal of tadalafil

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032766

Enrollment

100

Registered

2018-06-01

Start date

2015-05-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: treatment-naive patients with benign prostatic hyperplasia who have the international prostate symptom score of eight points or greater

Exclusion criteria

Exclusion criteria: urinary tract infection, acute urinary retention, prostate cancer, neurogenic bladder, the use of an alpha-1 adrenoceptor antagonist or anti-androgen, and a history of prostatic surgery

Design outcomes

Primary

Measure	Time frame
The persistence of tadalafil monotherapy and the reasons for withdrawal from treatment	—

Countries

Japan

Contacts

Public ContactYoshinori Yoshinori

Hokkaido Prefectural Esashi Hospital Division of Urology

rinoshiyokanata@me.com0139-52-0036

Outcome results